首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 以基因為基之藥物開發

市場調查報告書

商品編碼

2102996

表觀遺傳診斷市場－策略分析與預測（2026-2035）

Epigenetics Diagnostics Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年07月07日 | 出版商:

Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

表觀遺傳診斷市場預計將從 2026 年的 208 億美元成長到 2035 年的 638.2 億美元，複合年成長率為 13.3%。

表觀遺傳診斷專注於檢測基因表現中可遺傳的變化，而無需改變DNA序列。 DNA甲基化分析、組蛋白修飾分析、染色質免疫沉澱分析法、亞硫酸氫鹽定序和微陣列等技術正日益廣泛地應用於疾病早期檢測、預後判斷、患者分層和治療監測。隨著分子生物標記在醫療保健系統的常規臨床實踐中得到越來越廣泛的應用，腫瘤學、神經病學和罕見疾病診斷領域對該市場的需求強勁。定序技術、人工智慧數據分析和液態生物檢體平台的不斷進步，進一步加速了市場的擴張。

市場促進因素

癌症負擔日益加重

隨著全球癌症發生率的上升，對能夠早期識別疾病的高靈敏度診斷技術的需求持續成長。表觀遺傳生物標記，特別是DNA甲基化特徵，能夠實現早期檢測、腫瘤分類和治療監測，並為精準腫瘤學提供支援。

精準醫療的擴展

醫療機構正擴大將表觀遺傳生物標記納入個人化醫療方案。表觀遺傳診斷能夠提供有關基因表現調控、疾病進展和治療反應的重要訊息，從而改善患者分層和治療選擇。

分子技術的進步

生物資訊學領域的持續創新，包括利用次世代定序（NGS）、聚合酶鍊式反應（PCR）、亞硫酸氫鹽定序、微陣列和人工智慧等技術，正在提高診斷的靈敏度、特異性和擴充性。這些技術正在加速表觀遺傳學檢測的臨床應用。

液態生物檢體的廣泛應用

基於血液的表觀遺傳學檢測正逐漸成為一種有價值的非侵入性診斷工具，可用於癌症篩檢、早期檢測和微量殘存疾病的監測。基於甲基化的液態生物檢體的臨床有效性不斷提高，正推動其在醫療保健系統中得到更廣泛的應用。

市場限制因素

高昂的開發成本

表觀遺傳診斷檢測的開發和臨床檢驗需要大量投資、先進的實驗室基礎設施和高度專業的專業知識，這增加了商業化的成本。

缺乏標準化

分析方法、檢體品質和檢查室規程的差異持續影響檢查室間的可重複性和一致性。

複雜的監管要求

製造商必須證明新的表觀遺傳學診斷方法具有分析有效性、臨床效用和長期臨床療效，才能獲得監管部門的批准和保險覆蓋。

按產品/服務
- 裝置
- 試劑和耗材
- 軟體、生物資訊解決方案
- 診斷檢測服務
透過技術
- DNA甲基化分析
- 組蛋白修飾分析
- 染色質免疫沉澱分析法（ChIP）實驗
- 亞硫酸氫鹽定序
- ATAC-Seq 和染色質可及性分析
依樣本類型
- 血
- 組織
- 其他生物檢體
透過使用
- 瘤
- 神經病變
- 心血管疾病
- 自體免疫疾病
- 代謝性疾病
- 產前和生殖醫學
- 其他用途
最終用戶
- 醫院和臨床實驗室
- 參考檢查室
- 學術研究機構
- 製藥和生物技術公司
- 其他最終用戶

第10章：表觀遺傳學診斷市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：表觀遺傳學診斷市場：國別分析

美國
加拿大
德國
英國
法國
義大利
中國
日本
韓國
印度
澳洲
巴西
沙烏地阿拉伯

第12章競爭格局

市佔率分析
策略趨勢
企業合併、合作與聯盟
新產品發布

第13章：公司簡介

F. Hoffmann-La Roche Ltd
Illumina, Inc.
Thermo Fisher Scientific Inc.
QIAGEN NV
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
Merck KGaA
Pacific Biosciences of California, Inc.
Oxford Nanopore Technologies plc
Revvity, Inc.
Zymo Research Corporation
Active Motif, Inc.
Hologic, Inc.
Diagenode SA
New England Biolabs, Inc.

第14章：表觀遺傳學診斷市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-008387

The Epigenetics Diagnostics Market is estimated to grow to USD 63.82 billion in 2035 at a CAGR of 13.3% from USD 20.8 billion in 2026.

Epigenetics diagnostics focuses on detecting heritable changes in gene expression without altering the DNA sequence. Technologies including DNA methylation analysis, histone modification analysis, chromatin immunoprecipitation, bisulfite sequencing, and microarrays are increasingly being used for early disease detection, prognosis, patient stratification, and therapy monitoring. The market is witnessing strong demand from oncology, neurology, and rare disease diagnostics as healthcare systems increasingly integrate molecular biomarkers into routine clinical practice. Continuous improvements in sequencing technologies, artificial intelligence-based data interpretation, and liquid biopsy platforms are further accelerating market expansion.

Market Drivers

Growing Cancer Burden

The increasing incidence of cancer worldwide continues to drive demand for highly sensitive diagnostic technologies capable of identifying disease at earlier stages. Epigenetic biomarkers, particularly DNA methylation signatures, enable early detection, tumor classification, and treatment monitoring while supporting precision oncology.

Expansion of Precision Medicine

Healthcare providers are increasingly incorporating epigenetic biomarkers into personalized medicine programs. Epigenetic diagnostics provide valuable information regarding gene regulation, disease progression, and therapeutic response, improving patient stratification and treatment selection.

Advances in Molecular Technologies

Continuous innovation in next-generation sequencing (NGS), PCR, bisulfite sequencing, microarrays, and AI-assisted bioinformatics is improving diagnostic sensitivity, specificity, and scalability. These technologies are enabling broader clinical adoption of epigenetic testing.

Increasing Adoption of Liquid Biopsy

Blood-based epigenetic testing is emerging as a valuable non-invasive diagnostic tool for cancer screening, early detection, and minimal residual disease monitoring. Growing clinical validation of methylation-based liquid biopsy tests is supporting wider adoption across healthcare systems.

Market Restraints

High Development Costs

Developing and clinically validating epigenetic diagnostic assays requires substantial investment, advanced laboratory infrastructure, and highly specialized expertise, increasing commercialization costs.

Lack of Standardization

Variability in assay methodologies, specimen quality, and laboratory protocols continues to affect reproducibility and consistency across diagnostic laboratories.

Complex Regulatory Requirements

Manufacturers must demonstrate analytical validity, clinical utility, and long-term clinical benefit before new epigenetic diagnostics receive regulatory approval and reimbursement.

Market and Technology Insights

The global epigenetics diagnostics market can be segmented by product type, technology, application, end user, and geography.

By product type, the market includes reagents & kits, instruments, software & services, enzymes, and other products. Reagents and kits represent the largest segment because of their recurring use in molecular testing laboratories and compatibility with PCR and sequencing platforms.

By technology, the market comprises DNA methylation analysis, histone modification analysis, chromatin immunoprecipitation (ChIP), bisulfite sequencing, microarrays, and other epigenetic technologies. DNA methylation analysis remains the dominant technology because methylation biomarkers have demonstrated strong clinical utility in early cancer detection and disease monitoring.

By application, the market includes oncology, neurological disorders, autoimmune diseases, metabolic disorders, cardiovascular diseases, and other clinical applications. Oncology accounts for the largest share owing to the significant role of epigenetic alterations in tumor development and progression.

By end user, the market serves pharmaceutical & biotechnology companies, academic & research institutes, hospitals, diagnostic laboratories, and other healthcare organizations. Pharmaceutical companies increasingly utilize epigenetic diagnostics during biomarker discovery, companion diagnostic development, and precision medicine research.

Market Trends

The epigenetics diagnostics market continues evolving through technological innovation.

Key trends include:

Increasing adoption of DNA methylation-based diagnostics.
Expansion of liquid biopsy technologies.
Integration of artificial intelligence into biomarker analysis.
Growing implementation of precision medicine initiatives.
Increasing use of multi-omics approaches.
Expansion of companion diagnostics in oncology.
Continued investment in high-throughput sequencing platforms.

Regional Insights

North America remains the largest market because of advanced molecular diagnostic infrastructure, strong biotechnology investment, extensive cancer screening programs, and favorable regulatory support. The United States continues to lead commercialization of epigenetic diagnostic technologies.

Europe maintains a significant market share through coordinated genomics initiatives, strong research funding, and implementation of the In Vitro Diagnostic Regulation (IVDR), which is strengthening quality standards for molecular diagnostics.

Asia-Pacific is expected to experience the fastest growth due to increasing healthcare investment, expanding precision medicine programs, growing cancer incidence, and improving access to advanced molecular diagnostics. China, Japan, India, and South Korea are driving regional expansion.

Latin America and the Middle East & Africa are gradually expanding adoption of epigenetic diagnostics through healthcare modernization, increasing cancer awareness, and improving molecular diagnostic capabilities.

Competitive Landscape

The market includes major molecular diagnostics companies, life science tool providers, and biotechnology firms investing in sequencing technologies, methylation analysis, and precision oncology.

Major companies include Roche Diagnostics, Thermo Fisher Scientific, Illumina, Agilent Technologies, QIAGEN, Bio-Rad Laboratories, PerkinElmer, Diagenode, Active Motif, Abcam, Merck KGaA, Zymo Research, Hologic, and Element Biosciences. Companies continue strengthening their market positions through product launches, strategic collaborations, technology innovation, and expansion of precision diagnostic portfolios.

Future Outlook

The future of the epigenetics diagnostics market will be driven by broader clinical adoption of DNA methylation testing, expansion of liquid biopsy applications, integration of artificial intelligence with genomic analysis, and continued growth of precision medicine. Multi-omics platforms, single-cell epigenomics, and advanced bioinformatics are expected to improve disease detection, patient stratification, and treatment selection while expanding applications beyond oncology into neurology, cardiovascular disease, and rare disorders.

Conclusion

The Global Epigenetics Diagnostics Market is expected to experience robust growth through 2031, supported by increasing demand for precision diagnostics, rising cancer prevalence, and rapid technological innovation. Although assay standardization, regulatory complexity, and high development costs remain important challenges, continued advances in molecular diagnostics, liquid biopsy, next-generation sequencing, and artificial intelligence are expected to create substantial opportunities for diagnostic manufacturers, biotechnology companies, healthcare providers, researchers, and investors.

Key Benefits of this Report

Comprehensive assessment of the global epigenetics diagnostics market.
Detailed evaluation of technologies, applications, and emerging diagnostic trends.
Analysis of competitive strategies, regulatory developments, and commercialization opportunities.
Insights into liquid biopsy, DNA methylation analysis, and precision medicine.
Valuable resource for diagnostic manufacturers, biotechnology companies, laboratories, healthcare providers, researchers, investors, and policymakers.

What Businesses Use Our Reports For

Market opportunity assessment, product portfolio planning, competitive benchmarking, commercialization strategy, partnership evaluation, investment analysis, regulatory planning, precision medicine development, and long-term strategic decision-making.

Report Coverage

Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2031
Comprehensive analysis of the global epigenetics diagnostics market by product type, technology, application, end user, and geography
Evaluation of market dynamics, technological innovations, competitive landscape, regulatory environment, and future growth opportunities
Assessment of DNA methylation analysis, histone modification analysis, liquid biopsy, next-generation sequencing, artificial intelligence integration, precision medicine initiatives, and commercialization strategies
Analysis of reagents & kits, instruments, software & services, oncology, neurological disorders, autoimmune diseases, metabolic disorders, cardiovascular diseases, and emerging epigenetics diagnostic technologies through 2031.

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Epigenetics Diagnostics Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Industry Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast Analysis (2026-2035)
3.7 Epigenetic Biomarker Landscape
3.8 Molecular Diagnostics Workflow Overview
3.9 Testing Volume Analysis
3.10 User Adoption Analysis
3.11 Clinical Utility of Epigenetic Diagnostics
3.12 Precision Medicine and Companion Diagnostics Landscape

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Technologies in Epigenetics Diagnostics
6.2 Product Innovation Analysis
6.3 DNA Methylation Analysis Advancements
6.4 Histone Modification Detection Technologies
6.5 Chromatin Accessibility Profiling Innovations
6.6 Clinical Trial Analysis
6.7 Pipeline Analysis
6.8 AI Integration in Epigenomic Data Interpretation
6.9 Digital Health and Bioinformatics Integration
6.10 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Epigenetics Diagnostics Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Epigenetic Biomarker Type
8.3 Analysis by Diagnostic Technology
8.4 Analysis by Sample Type
8.5 Analysis by Clinical Application
8.6 Analysis by Testing Setting
8.7 Analysis by End User

9. Epigenetics Diagnostics Market Segment Analysis (2021-2035)

9.1 By Product & Service
- 9.1.1 Instruments
- 9.1.2 Reagents & Consumables
- 9.1.3 Software & Bioinformatics Solutions
- 9.1.4 Diagnostic Testing Services
9.2 By Technology
- 9.2.1 DNA Methylation Analysis
- 9.2.2 Histone Modification Analysis
- 9.2.3 Chromatin Immunoprecipitation (ChIP)-Based Assays
- 9.2.4 Bisulfite Sequencing
- 9.2.5 ATAC-Seq and Chromatin Accessibility Assays
9.3 By Sample Type
- 9.3.1 Blood
- 9.3.2 Tissue
- 9.3.3 Other Biological Samples
9.4 By Application
- 9.4.1 Oncology
- 9.4.2 Neurological Disorders
- 9.4.3 Cardiovascular Diseases
- 9.4.4 Autoimmune Diseases
- 9.4.5 Metabolic Disorders
- 9.4.6 Prenatal & Reproductive Health
- 9.4.7 Other Applications
9.5 By End User
- 9.5.1 Hospitals & Clinical Laboratories
- 9.5.2 Reference Laboratories
- 9.5.3 Academic & Research Institutes
- 9.5.4 Pharmaceutical & Biotechnology Companies
- 9.5.5 Other End Users

10. Epigenetics Diagnostics Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Epigenetics Diagnostics Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 China
11.8 Japan
11.9 South Korea
11.10 India
11.11 Australia
11.12 Brazil
11.13 Saudi Arabia

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches

13. Company Profiles

13.1 F. Hoffmann-La Roche Ltd
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Recent Developments
13.2 Illumina, Inc.
13.3 Thermo Fisher Scientific Inc.
13.4 QIAGEN N.V.
13.5 Agilent Technologies, Inc.
13.6 Bio-Rad Laboratories, Inc.
13.7 Merck KGaA
13.8 Pacific Biosciences of California, Inc.
13.9 Oxford Nanopore Technologies plc
13.10 Revvity, Inc.
13.11 Zymo Research Corporation
13.12 Active Motif, Inc.
13.13 Hologic, Inc.
13.14 Diagenode SA
13.15 New England Biolabs, Inc.